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Successful vaccine development for infectious diseases has largely been achieved in settings where natural
immunity to the pathogen results in clearance in at least some individuals. HIV presents an additional
challenge in that natural clearance of infection does not occur, and the correlates of immune protection
are still uncertain. However, partial control of viremia and markedly different outcomes of disease are
observed in HIV-infected persons. Here, we examine the antiviral mechanisms implicated by one variable
that has been consistently associated with extremes of outcome, namely HLA class I alleles, and in particular
HLA-B, and examine themechanisms bywhich thismodulation is likely to occur and the impact of these inter-
actions on evolution of the virus and the host. Studies to date provide evidence for both HLA-dependent and
epitope-dependent influences on viral control and viral evolution and have important implications for the
continued quest for an effective HIV vaccine.Introduction
HIV infection is typically associatedwith an acute viral syndrome,
with subsequent resolution of symptoms and then an 8–10 year
asymptomatic period until the development of AIDS, defined
in adults by a decline in CD4+ T cell number to fewer than
200 cells/mm3 or the presence of certain AIDS-defining illnesses
that reflect underlying immune deficiency. Remarkably, how-
ever, the kinetics of progression to AIDS differ from a course
as short as 1 year or less to a lack of disease progression after
more than 35 years and counting in some rare individuals. The
one parameter that has been repeatedly predictive of the course
of disease is human leukocyte antigen (HLA) class I, clearly indi-
cating a role for host genetics in outcome of HIV infection.
The major histocompatibility complex (MHC) coding region,
known as HLA in humans and situated on the short arm of chro-
mosome 6, is themost polymorphic of the entire human genome.
The single most polymorphic gene locus within this region is the
HLA class I locus, for which 4,269 different HLA-A, HLA-B, and
HLA-C molecules have been described (Robinson et al., 2011).
The explanation for this extreme polymorphism is that differ-
ences between the HLA class I alleles expressed can have
a major impact on the incidence of, and survival from, a wide
variety of infectious diseases, inflammatory conditions, autoim-
mune diseases and malignancies (Hindorff et al., 2012).
The reason for these associations between HLA and disease
outcome becomes clear when one examines the structure and
function of HLA class I. In 1974, Zinkernagel and Doherty
demonstrated that MHC class I molecules are directly involved
in the ability of CD8+ T cells to recognize and kill virus-infected
cells (Zinkernagel and Doherty, 1974), a phenomenon termed
MHC class I restriction, and subsequently proposed that infec-
tious diseases drive MHC class I polymorphism (Doherty and
Zinkernagel, 1975). HLA molecules bind fragments of host or
pathogen-derived proteins that have been processed intracellu-
larly and transported into the endoplasmic reticulum by TAP (the
transporter associated with antigen processing), where they426 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.associate with developing class I molecules and are then trans-
ported to the cell surface. CD8+ T cells that recognize self-
peptides bound to MHC class I molecules and expressed on
the cell surface are deleted by negative selection in the thymus,
providing T cells ameans to recognize non-self proteins and thus
defend against intracellular pathogens. Thus, HLA class I is inte-
gral to the immune system being able to differentiate infected
from noninfected cells.
The advent of structural data on the HLA class I-peptide
complex led to a clearer understanding of the specificity of
immune recognition. In 1987, Bjorkman et al. revealed the 3D
structure of the surface-expressed HLA class I molecule, con-
sisting of a highly variable heavy chain comprising three alpha
domains in complex with a soluble invariant molecule, b2 micro-
globulin (Bjorkman et al., 1987a, b). The alpha 1 and alpha 2
domains combine to make a four-stranded b sheet lined by
two antiparallel helices, which together form a deep groove
that binds self- or foreign peptide. This structural analysis iden-
tified 57 accessible HLA residues within the alpha 1 and alpha
2 domains that form the peptide binding groove and that poten-
tially interact with bound peptide or T cell receptor. Calculation of
numbers of synonymous (dS) and nonsynonymous (dN) nucleo-
tide substitutions per site, a measure of selection pressure,
demonstrated that, for these 57 codons encoding the peptide
binding region, dN/dS ratios were strikingly high (more than three
in each of HLA-A, -B, and -C), whereas for the codons encoding
the remainder of the a1 and a2 domains, dN/dS ratios in each
casewere <0.4 (Hughes and Nei, 1988). Thus, purifying selection
operates to maintain HLA amino acid sequences outside the
peptide-binding region, whereas positive selection resulting
from dramatically divergent HLA-associated disease outcomes
is focused on the residues that constitute the peptide-binding
region.
In this Review, we will first evaluate the consistency of associ-
ations between expression of HLA class I molecules and HIV
disease outcome, focusing in particular on HLA-B alleles, for
Table 1. Consistent HLA Associations with Variation in HIV
Disease Progression
HLA-B References Cohorts
Protective HLA I Alleles
B*13:02 Honeyborne et al., 2007;
Fellay et al., 2009;
Pereyra et al., 2010
C clade South Africa;
B clade Caucasian
B*14/14:02 Pereyra et al., 2010;
Lazaryan et al., 2011
B clade Caucasian;
African American
B*27/27:05 Kaslow et al., 1996;
O’Brien et al., 2001,
B clade Caucasian
Fellay et al., 2009;
Pereyra et al., 2010
B*42:01 Carlson et al., 2012 C clade South Africa/
Botswana/Zimbabwe
B*44:03 Leslie et al., 2010;
Carlson et al., 2012
C clade, South Africa;
South Africa/Botswana/
Zimbabwe
B*51 Kaslow et al., 1996;
O’Brien et al., 2001
B clade Caucasian
B*52:01 Pereyra et al., 2010 B clade Caucasian
B*57/B*57:01 Kaslow et al., 1996;
Migueles et al., 2000;
O’Brien et al., 2001;
Pereyra et al., 2010
B clade Caucasian;
Caucasian/Hispanic
B*57:02 Leslie et al., 2010 C clade South Africa
B*57:03 Costello et al., 1999;
Leslie et al., 2010
A clade Rwanda;
C clade South Africa
Tang et al., 2010;




B*57:03 Pereyra et al., 2010;
Lazaryan et al., 2011
B clade African
American
B*58:01 Kiepiela et al., 2004;
Lazaryan et al., 2006
C clade South Africa;
Zambia
Carlson et al., 2012 C clade South Africa/
Botswana/Zimbabwe
B*81:01 Kiepiela et al., 2004;
Tang et al., 2010
C clade, South Africa;
Zambia; South Africa/
Botswana/Zimbabwe
Carlson et al., 2012;
Pereyra et al., 2010
B clade African
American; C clade
A*25/25:01 Kaslow et al., 1996;
Pereyra et al., 2010
B clade Caucasian
A*32/32:01 Kaslow et al., 1996;
Fellay et al., 2009
B clade Caucasian;
Lazaryan et al., 2011 B clade North American
African American
A*74/74:01 Tang et al., 2010;
Matthews et al., 2011;
Lazaryan et al., 2011;
Koehler et al., 2010




clades A, C, D, Tanzania
Disease-Susceptible HLA I Alleles
B*07:02 Pereyra et al., 2010 B clade Caucasian
B*08/08:01 Steel et al., 1988;




Carlson et al., 2012 C clade South Africa/
Botswana/Zimbabwe
B*18/18:01 Leslie et al., 2010;
Carlson et al., 2012
C clade South Africa/
Botswana/Zimbabwe
B*35 Carrington et al., 1999;
O’Brien et al., 2001
B clade Caucasian
B*35:01 Pereyra et al., 2010 B clade North
American European
B*35:02/35:03 Gao et al., 2001;
Fellay et al., 2009
B clade Caucasian
B*45/45:01 Tang et al., 2010;




B*51:01 Carlson et al., 2012 C clade South Africa/
Botswana/Zimbabwe
B*53:01 Gao et al., 2001;
Pereyra et al., 2010
B clade Caucasian;
African American
B*54/55/56 Hendel et al., 1999;
Dorak et al., 2003
B clade Caucasian
B*58:02 Kiepiela et al., 2004;
Tang et al., 2010;
C clade South Africa;
Zambia
Carlson et al., 2012 South Africa/Botswana/
Zimbabwe
A*36:01 Tang et al., 2010;




B*07:02 Pereyra et al., 2010 B clade Caucasian
B*08/08:01 Steel et al., 1988;
Pereyra et al., 2010;
B clade Caucasian
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Reviewwhich the strongest data exist. We will then consider the poten-
tial mechanisms underlying these associations, including the
nature of protective HLA class I alleles themselves and their
interactions with CD8+ T cells and other binding partners and
the specific epitopes presented within the binding groove. Deci-
phering these, and how they might be manipulated to augment
immune control, is central to efforts to contain HIV through
vaccine development.
HLA-HIV Disease Outcome Studies
HLA class I alleles have consistently been the strongest indepen-
dent associations, genetic or otherwise, with differential rates of
HIV disease outcome. The first large population study showing
a modulating role for HLA class I alleles in HIV infection revealed
a relationship between HLA profile and time to onset of AIDS,
with HLA-B*27 and HLA-B*57 having the highest impact on
slowing the course of disease (Kaslow et al., 1996). This was
followed by numerous additional studies in both acute and
chronic infection, ultimately providing multiple independent
documentations of this HLA impact. The most consistent of
these observations for HIV disease association in relation to
particular HLA-A and HLA-B alleles are shown in Table 1.
Improvements in HLA typing techniques have enhanced the
ability to identify HLA associations with HIV disease outcome.
Since the early 1990s, due to the advent of molecular- ratherImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 427
Figure 1. Defined HLAClass I and Class II Alleles by Year from 1968–
2012
Graph taken from http://www.ebi.ac.uk/imgt/hla/intro.html, copyright SGE
Marsh 07/2012, with permission.
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able class I alleles have increased 100-fold (Figure 1). This
increase comes not just from detection of new alleles but also
from the ability tomolecularly differentiate alleles that were previ-
ously indistinguishable by antibody-based techniques. Current
typing via direct sequencing of exons 2 and 3, which encode
the a1 and a2 extracellular domains, is a substantial advance,
with the first two digits specifying a group of alleles (for example,
HLA-B*15), and the third through fourth or fifth specifying distinct
HLA molecules (for example, HLA-B*15:01 through HLA-
B*15:254, given that there are 254 distinct HLA-B*15molecules).
With improved typing technology to better define the extent of
HLA diversity, and the use of large study cohorts, the ability to
detect substantial HLA associations with HIV disease outcome,
even for rare alleles, has improved. For most populations, where
perhaps 60–70 different HLA class molecules are expressed at a
phenotypic frequency of 1% or greater, a minimum of 500–1,000
subjects are needed to have a realistic chance of detecting a
significant effect for an individual HLA allele, depending on the
frequency of the allele and the size of the effect. However, an
important challenge in determining the HLA allele responsible
for a particular observed effect on HIV disease outcome is the
issue of linkage disequilibrium (LD). For this reason, the impact
of individual HLA-C alleles is not included in Table 1 because it
remains unclear the extent to which their appearance in HLA-HIV
disease association studies is simply due to LD with certain
HLA-B alleles. The HLA-C alleles that have been associated
with protection against HIV disease progression tend to be in
LD with protective HLA-B alleles (for example, the HLA-
C*18:01 in LD with HLA-B*57:03 and with HLA-B*81:01), and
similarly for disease-susceptible HLA-C alleles (such as HLA-
C*07:02 and HLA-B*07:02). In Caucasian populations, where
the disease-susceptible allele HLA-B*58:02 is largely absent,
and the protective allele HLA-B*57:01 is in tight LD with HLA-
C*06:02, HLA-Cw*06:02 may appear protective. Conversely,
in African populations where HLA-B*57:01 is largely absent,
HLA-B*58:02 is highly prevalent and in LD with HLA-C*06:02,428 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.so HLA-C*06:02 may appear disease susceptible (Kiepiela
et al., 2004; Leslie et al., 2010).
The Dominant Role of HLA-B
Some important observations may be made from the list of
MHC I molecules shown in Table 1. First, HLA-B, which consti-
tute 1,898 of the 4,269 distinct HLA class I A, B, and Cmolecules
described thus far, form the majority of the HLA class I alleles for
which associations with either slow or rapid progression to HIV
disease have been identified. The most dramatic of these is
HLA-B*57:01, which is the most highly enriched of all HLA alleles
in persons who control HIV spontaneously (Emu et al., 2008; Mi-
gueles et al., 2000; Pereyra et al., 2008). Second, the protective
HLA-B alleles are not broadly similar to one another, nor are the
disease-susceptible HLA-B alleles similar to one another.
Rather, these arise from several different supertypes, which
are defined by similarities in peptide-binding motif (Sidney
et al., 2008). Among these supertypes are B07 (HLA-B*07:02,
HLA-B*35, HLA-B*42:01, HLA-B*51:01, HLA-B*53, and HLA-
B*81:01), B27 (HLA-B*14 and HLA-B*27:05), B44 (HLA-B*18,
HLA-B44:03, and HLA-B*45:01), B58 (HLA-B*57, HLA-B*58:01,
and HLA-B*58:02), B62 (HLA-B*52:01), and unclassified (HLA-
B*13:02). Of note, dramatic differences in outcome in HIV clade
C virus infection are associated with HLAHLA-B*58:01 and HLA-
B*58:02, both from the same supertype and differing by only
three amino acids (Kiepiela et al., 2004; Ngumbela et al., 2008).
Third, HLA-B*51:01 appears to be both protective and disease
susceptible, depending on the geographic and evolutionary con-
text. This reflects both the dynamic nature of HLA-HIV disease
progression associations and also their HIV clade dependence.
There is evidence that HLA-B*51:01 was protective early on in
the B clade epidemic, but that the rapid accumulation of
escape mutants at the population level within the dominant
HLA-B*51:01-restricted CD8+ T cell epitope (TAFTIPSI, RT aa
128–135) has reduced its protective effect (Kawashima et al.,
2010; Kawashima et al., 2009). It appears also that this protective
effect may be clade specific, with HLA-B*51:01 being linked with
disease progression in C clade infection (Carlson et al., 2012).
Similarly, HLA-B*35:01 is not disease susceptible in C clade
infection, where the dominant Gag epitope NPPIPVGDIY (Gag
253–262) is highly targeted; however, in B clade infection, where
HLA-B*35:01 is associated with rapid disease progression (Gao
et al., 2001; Lazaryan et al., 2011; Pereyra et al., 2010), this Gag
epitope is not targeted. The reason for this is that the B clade
version NPPIPVGEIY is nonimmunogenic, owing to the reduced
peptide-MHC binding stability brought about by the D260E
substitution at P8 in the epitope (our unpublished data).
HLA class I alleles are further divided into so-called private
and public allotypes on the basis of the particular amino acids
expressed at residues 77 and 80–83 in the alpha 1 helix that
determine the public allotypes Bw4 and Bw6. HLA residues 77,
80, and 81 make contributions to the F pocket of the peptide
binding groove, which forms the C-terminal anchor, and there-
fore influence the epitopes that can be presented to CD8+
T cells; however, this region also makes important interactions
with NK cells. Although most protective HLA class I molecules
carry the Bw4 motif, and most disease-susceptible molecules,
the Bw6 motif (Flores-Villanueva et al., 2001), there are several
exceptions to this pattern: HLA-B*14, HLA-B*42:01, and
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progression, and HLA-B*53:01 and HLA-B*58:02 are Bw4 alleles
associated with rapid progression. Also, although the few HLA-A
alleles that have been linked with slow disease progression
include HLA-A*25:01 and HLA-A*32:01, both expressing the
Bw4 motif, other HLA-A molecules such as HLA-A*23 and
HLA-A*24 that carry the Bw4 motif are not protective, and
HLA-A*74:01, which differs from HLA-A*32:01 almost exclu-
sively in not carrying the residues that constitute the Bw4 motif,
is nonetheless consistently protective against HIV disease
progression (Carlson et al., 2012; Koehler et al., 2010; Lazaryan
et al., 2011; Matthews et al., 2011; Tang et al., 2010).
Potential Structural Mechanisms of HLA Class
I-Mediated Control of HIV
The consistent observation that certain class I alleles are associ-
ated with relative protection from disease progression and
others with risk of progression suggests that specific structural
properties of this highly polymorphic complex might influence
outcome.
Insights from Host Gene Sequencing
A number of genomewide association studies (GWASs) have
shown that single-nucleotide polymorphisms (SNPs) within the
HLA class I region have the strongest genetic association with
durable control of HIV (Dalmasso et al., 2008; Fellay et al.,
2007; Limou et al., 2009; Pereyra et al., 2010), in particular
a SNP that is in strong LDwith HLA-B*57 and another associated
with HLA-C expression. Although it had been already estab-
lished that there was a strong HLA-B*57 effect on HIV disease
progression (Kaslow et al., 1996; Migueles et al., 2000), these
initial GWAS studies clearly showed that themajor genetic signal
associated with a viral set point is exclusively within the HLA and
that no other genetic associations reached statistical signifi-
cance, giving a sense of magnitude of the HLA effect. A major
limitation of GWAS studies, however, is the issue of LD, given
that measurements are only made of specific tagging SNPs,
each of which is in LD with multiple other SNPs that may be
causal.
A higher power view of the genetic impact of HLA on viral
control arose from coupling GWAS data with sequencing within
the HLA locus (Pereyra et al., 2010). A novel imputation method
to assign sequence within the HLA (de Bakker et al., 2006) al-
lowed comparison of persons classified as HIV controllers (VL
< 2000 copies) with typical progressors (VL > 10,000 copies).
That study, which extended previous GWAS studies by allowing
assessment of the effect of individual amino acid positions on
HIV control, showed that the most significant independent
genetic associations with viral control relate to specific amino
acids within the HLA peptide-binding groove that are involved
in binding to the viral peptide. The strongest amino acid associ-
ation with both control and lack of control is the allelic variant at
position 97 within the HLA-B peptide binding cleft, which forms
part of the C pocket and helps to anchor the viral peptide and
thus probably influences the 3D structure of this complex. Inter-
estingly, HLA-B*58:01 and HLA-B*58:02, associated with
extremes of outcome in clade C virus infection, differ only at
positions 94, 95, and 97 (Marsh et al., 2000). An important point
is that position 97, which has six allelic variants, remains statis-
tically significant even after controlling for HLA-B*57 and HLA-B*27, alleles known to be associated with host control (Pereyra
et al., 2010). Amino acid variability at position 97 affects structure
and flexibility of the peptide-binding groove, being implicated
both in HLA protein folding and also in cell surface expression
(Blanco-Gelaz et al., 2006; Fagerberg et al., 2006).
Other amino acidsmarkedly impacting viral loadwere found to
line the HLA-B peptide-binding groove, likewise interacting with
bound peptide. An effect of HLA-C was also identified in these
studies, but this contribution is likely due to variable expression
levels modulated by a specific microRNA rather than the actual
physicochemical properties of the structure itself (Kulkarni
et al., 2011). The impact of HLA-C expression may relate to the
fact that, unlike HLA-A and HLA-B, HLA-C is not downregulated
by Nef, leaving infected cells still potentially susceptible to HLA-
C-restricted immune responses (Cohen et al., 1999). The exact
mechanism whereby alterations in the HLA-B-binding groove
influence control remain unclear, but variability at the same
amino acid positions in the HLA-binding groove reconcile both
protective and risk HLA-B alleles.
The Potential Importance of HLA-Binding Motifs
The above studies suggest that specific structural features
within the peptide-binding groove of the HLA class I are impor-
tant for immune control of immunodeficiency virus infection, and
a review of the peptide-binding motifs of HLA class I molecules
(Table 2) provides additional support for this hypothesis. These
relate in particular to the nature of the B pocket, which binds
position 2 (P2) of the peptide, and the F pocket, which binds
the carboxy-terminal amino acid of the peptide (PC), with
characteristics that are consistent across species. For example,
the peptide-binding motif of the protective MHC class I allele
Mamu-B*08 in simian immunodeficiency virus (SIV) infection is
remarkably similar to that of the protective allele HLA-B*27 in
HIV infection in humans, with a strict requirement for the self
or viral peptide to contain Arg at P2, a strong preference for
Arg (or Lys) at P1, and for medium-size hydrophobic residues
at PC. This observation reflects convergent evolution in these
species, both evolving a similar binding motif. It has been
proposed that the preference of Mamu-B*08 and HLA-B*27,
for peptides carrying Arg both at P1 and P2, may mean that
the epitopes restricted by these alleles are located in protein
regions of particular structural significance, that is, contain-
ing adjacent Arg residues and being as a result highly resis-
tant to mutation (Mudd et al., 2011). There is also similarity in
the peptide-binding groove of the protective macaque allele
Mamu-B*17 and HLA-B*57/58:01, HLA-A*25, and HLA-A*32,
all of which have a strong preference for Trp at PC. It is note-
worthy that of the 50 HLA-B molecules for which peptide-
binding motifs are listed in The HLA Facts Book (Marsh et al.,
2000), with one exception, only HLA-B*57 and HLA-B*58:01,
both protective alleles, have Trp as a primary anchor residue
at that position. The exception is HLA-B*15:13, which contains
Trp as a sole anchor at PC, but it is sufficiently rare that its
capacity as a protective allele or otherwise is unknown. HLA-
B*27 alleles are the only HLA-B alleles with Arg exclusively as
a primary anchor residue.
These observations prompt the hypothesis that there is
a particular significance to the peptide-MHC interactions that
involve either Arg or Trp and the complementary binding pocket
into which these residues precisely fit. Both amino acids areImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 429
Table 2. Dominant Epitopes Restricted by MHC Class I Alleles Associated with Protection in HIV/SIV Infection
This table contains the following references (exclusive of the main text): Allen et al. (2001), Brander et al. (1999), Goulder et al. (2000), Goulder et al.
(1996), Harrer et al. (1996), Klenerman et al. (1996), Nixon et al. (1988), Nomura and Matano (2012), and Smith et al. (2005). Peptide-binding motifs
are reviewed in Marsh et al., 2000. N/A, peptide-binding motifs not determined.
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charged of all the amino acids (the pKa of the side chain is
12.48) and also has a three-carbon aliphatic straight chain, pro-
viding a long finger-like projection with the positively charged
guanidium group at its tip, fitting perfectly into the B pocket of
HLA-B*27 (Madden et al., 1993). The fact that Arg appears to
be irreplaceable in this position is evidence of the quality of fit.
Studies of the stability of HLA-B*27 influenza, EBV, and HIV-
specific peptide-MHC complexes confirm that, in each case,430 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.the Arg at P2 contributes the most to peptide-MHC stability,
even when the peptide carries Arg at PC, as it does in the EBV
epitope (Stewart-Jones et al., personal communication). It is
possible that the preference for Arg at both P1 and P2 for
Mamu-B*08 and B*27 may critically increase the stability of such
peptide-MHC complexes. Thus, the complementarity of the
anchor-binding pocket to Arg appears critical, but what specific
advantage such peptide stability might confer, for example on
the avidity of TCR binding or on TCR signaling, is not clear.
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amino acids (molecular weight 203), and its precise shape com-
plementarity with the appropriate F pocket, such as provided by
HLA-B*57, allows greater stability as a result of the higher
number of interatomic van der Waal’s interactions than would
be generated by smaller anchor residues in smaller pockets.
The HLA-B*57:03-KAFSPEVIPMF complex has 46 interatomic
van der Waal’s contacts between Phe at PC and the F pocket,
the HLA-B*57:03-KAFSPEVI complex has 30, and the HLA-
B*57:03-ISPRTLNAW complex has 86 van der Waal’s contacts
between Trp at the C terminus and the F pocket (Stewart-Jones
et al., 2005). These considerations prompt the speculation that
those MHC class I molecules that have anchor-binding pockets
that are precisely complementary to Arg (such as the HLA-B*27
and Mamu-B*08 B pockets, and perhaps also the HLA-A*74:01
F pocket) or to Trp (such as HLA-B*57/5801, HLA-A*25, HLA-
A*32, and Mamu-B*17 F pockets) may have the capacity to
bind peptidesmore stably and contribute to the immunodomina-
tion of CD8+ T cell responses restricted by these alleles (Altfeld
et al., 2006).
One additional particular feature of Trp, distinct from all the
other amino acids, is that it is encoded by only one codon,
UGG. Single-nucleotide changes from this result either in a
stop codon (UGA, UAG) or a codon encoding dramatically
different amino acids such as Gly, Cys, Ser, or Arg, any of which
would be likely to have very significant structural consequences
were they to replace Trp. Thus, mutational escape might be
more problematic in this instance than is the case for Tyr-Phe
or Ile-Leu substitutions, for example, which might be sufficient
to reduce epitope recognition without significantly altering
protein function.
The nature of the HLA peptide-binding pockets may also
modulate immune responses through an impact on thymic
selection, which is governed by the strength of interaction of
self-peptides presented within the peptide-binding groove and
the TCR. The signal delivered to the T cell has to be of sufficient
magnitude to promote proliferation (positive selection), and yet
not too strong or the clonal response will be deleted (negative
selection). One computational study has shown that HLA alleles
having the strongest association with protection from HIV
disease progression, namely B*57 and B*27, are predicted to
bind the fewest self-peptides of those HLA alleles evaluated,
whereas alleles most associated with risk bind greater numbers
of self-peptides (Kosmrlj et al., 2010). T cells restricted by HLA-
B*57 and B*27 would have undergone less negative selection
given that they are selected against fewer self peptides, and so
a greater number would probably survive thymic selection, and
these would be predicted to be more likely to be cross-reactive.
Experimental data will be required to validate this hypothesis.
Kinetics and Magnitude of HLA Class I-Peptide
Expression
Most data on HIV-specific CD8+ T cell responses in humans and
in monkey models have been generated in the context of
peptide-sensitized target cells rather than infected cells. Few
studies have actually examined infected cells in which CTL
recognition is dependent upon antigen processing (examples
include Chen et al., 2012a; Chen et al., 2011; Chen et al., 2009;
Draenert et al., 2004; Migueles et al., 2002; Migueles et al.,
2008; Sa´ez-Cirio´n et al., 2007; Yang et al., 1996; Yang et al.,2003). Where antigen processing has been evaluated, variation
in the kinetics of presentation of viral epitope are observed
because of differences in processing that depend on the flanking
sequences (Draenert et al., 2004; Le Gall et al., 2007) or because
of cell type-specific differences in processing (Lazaro et al.,
2009; Steers et al., 2011). Moreover, it appears that there is
a kinetic advantage to targeting Gag and Pol, given that pre-
formed Gag and Pol protein that enter the cell upon infection
are rapidly degraded and processed through the class I
pathway, whereas proteins such as Env must be endogenously
processed (Chen et al., 2012a; Payne et al., 2010; Sacha et al.,
2007a; Sacha et al., 2007b). The kinetics of epitope expression
may be particularly important as a result of Nef-mediated down-
regulation of surface HLA class I expression. The selective
downregulation of HLA-A and HLA-B by Nef protects infected
cells from immune recognition by CTL (Collins et al., 1998;
Yang et al., 2002), but because Nef does not downreglate
HLA-C, they are not susceptible to NK cell-mediated attack (Co-
hen et al., 1999). Interestingly, one study showed Nef downregu-
lation of HLA-A was observed to be consistently more efficient
than downregulation of HLA-B (Cohen et al., 1999), perhaps
contributing to the dominance of HLA-B-restricted responses
associated with lowering of viremia. However, HLA-associated
differences in susceptibility to Nef-mediated downregulation
was not observed in a careful comparative study of HLA-A*02
and HLA-B*57:01 (Chen et al., 2012a; Chen et al., 2011).
HLA Effects on CD8+ T Cell Function
The proximate ligand for the peptide-HLA complex is the T cell
receptor (TCR) on cytotoxic T lymphocytes, suggesting that
HLA-dependent differences in CD8+ T cell function might
account for the observed HLA-mediated effects. The functional
profile of CD8+ T cells (effector cytokine secretion and degranu-
lation) has been shown to be enhanced for HLA-B*27:05 HIV-
infected persons with both high and low viral loads, suggesting
an HLA-specific effect on effector function (Almeida et al.,
2007). Similar HLA-associated effects on HIV-specific CD8
T cell proliferation have also been suggested (Horton et al.,
2006) and may also regulate the immunomodulatory effects of
T regulatory cells (Elahi et al., 2011). The strongest correlation
with in vivo control has been the in vitro proliferative capacity
of CD8+ T cells after antigen-specific stimulation, as originally
shown with autologous HIV-infected CD4+ T cells (Migueles
et al., 2002). In these same experiments, no differences were
observed from quantitative assessments by IFN-g production
or by tetramer staining. Notably, the strongest levels of prolifer-
ation have been associated with protective HLA alleles (Horton
et al., 2006), and at least some studies have shown proliferative
responses restricted by the most protective alleles, HLA-B*57
and HLA- B*27, to persist to some extent even with progressive
infection (Horton et al., 2006; Migueles et al., 2002), suggesting
HLA-dependent effects on CD8+ T cell proliferation. Indeed,
in situations in which epitope-specific responses have been
compared, proliferation associated with HLA-B*27- and HLA-
B*57-restricted epitopes has been much greater than prolifera-
tion of other epitope-specific responses in the same individuals
(Horton et al., 2006; Migueles et al., 2002). However, comparison
of controllers and progressors expressing protective HLA alleles
indicate that the effect is not only due to the HLA allele itself,
given that clear differences in proliferation have been shownImmunity 37, September 21, 2012 ª2012 Elsevier Inc. 431
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Migueles et al., 2008). However, whether this difference is CD8+
T cell intrinsic or related to differences in CD4+ T helper cell
function is unclear (Chen et al., 2012b; Lichterfeld et al., 2004).
A number of studies have begun to shed light on the mecha-
nisms that may be responsible for the link among HLA, T cell
function, and viral control. Lytic granule loading by CD8+
T cells and delivery of granzyme B to infected target cells either
after 6 days of stimulation in vitro or within as short a time as
30 min has been associated with enhanced killing of infected
cells and enhanced inhibition of HIV replication in vitro (Chen
et al., 2012b; Hersperger et al., 2011; Migueles et al., 2002;
Migueles et al., 2008). The potential role of specific TCR usage
has also been examined, suggesting that public TCR usage,
meaning TCRs specific for the same response that are identical
or near identical in different individuals, may be more common in
persons who control HIV. However, clonal composition does not
appear to differentiate controllers compared to progressors
(Chen et al., 2012b; Mendoza et al., 2012), and the role of avidity
remains controversial (Bennett et al., 2008; Chen et al., 2012b;
Iglesias et al., 2011).
In a study of HLA-B*27:05-positive infected persons, all of
whom targeted the same epitope in Gag (designated KK10)
and had no detectable escape mutations with that epitope, a
comparison of HIV controllers compared to progressors re-
vealed that the antiviral efficacy of the CTL differed significantly
between these groups (Chen et al., 2012b). TCR in controllers
not only had a greater ability to recognize infected cells and
inhibit virus replication in an in vitro culture system, but were
also more cross-reactive with variants within the epitope that
are known to arise in vivo. These studies show a significant
impact of TCR usage in modulating the protective effect of class
I alleles. Similar results were also found for the protective allele
HLA-B*57 in that study. Interestingly, other parameters including
magnitude, polyfunctionality, and functional avidity did not cor-
relate with control in the small cohort studied, indicating that
those effects may be minor compared to the impact of TCR.
CTL engagement of target cells is not just comprised of a TCR-
peptide-MHC interaction, but is also influenced by binding of the
CD8 receptor to a region of the a3 domain of the HLA. The
likelihood that this interaction has an influence on CTL efficacy
is suggested by a recently completed GWAS and imputed amino
acid sequence analysis of African Americans, which demon-
strated not just residues in the HLA-B binding groove as being
important, but also the allelic form of aa position 245, which is
directly involved in CD8 binding to the peptide-MHC complex
(McLaren et al., 2012). This position is monoallelic in Caucasians
but biallelic in African Americans and suggests that residues
outside the HLA binding groove are also important. It is note-
worthy, however, that the protective HLA-B*81 is one of the
HLA molecules, together with HLA-B*48 and HLA-A*68:01,
carrying a variant at HLA residue 245 that reduces CD8-binding
affinity. The relationship, if any, of this polymorphism to HIV
disease progression thus remains unclear.
Other HLA Binding Partners
The HLAmolecule interacts not just with the TCR onCTL through
the a2 and a3 domains in the context of a presented viral
peptide, but also with other binding partners through other cells.
Of particular potential importance is their involvement in innate432 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.immunity as ligands for the killer cell immunoglobulin-like recep-
tors (KIRs), which modulate natural killer cell activity, the first line
of defense against virally infected and cancer cells (Carrington
et al., 2008). NK cells are actively inhibited by cells that express
HLA class I, but go on the attack against cells that are missing
class I or have downregulated it, as occurs with certain cancers
and virus infections. There are many different NK cell receptor
families, but KIR genes are the most polymorphic, consistent
with an active role in modulating HIV disease outcome. One of
these interactions occurs between HLA class I and products
of the KIR3DL1 and KIR3DS1 genes. KIR3DL1, an inhibitory
receptor, interacts with its binding partner Bw4 expressed on
40% of HLA-B alleles. It is through this KIR-HLA interaction
that Nef-mediated downregulation of HLA-B may sensitize in-
fected cells for recognition by NK cells. Certain KIR alleles are
associated with improved outcome, in particular KIR3DL1 in
the presence of HLA-B molecules expressing Bw4 that contain
an Ile at position (Bw4-80I) (Martin et al., 2007). KIR3DS1, which
encodes an activating receptor, is also protective against
disease progression in the setting of Bw4-80I (Martin et al.,
2002). The mechanisms that are operating are not entirely clear
(Altfeld and Goulder, 2007), but may involve direct lysis or anti-
body-dependent cell-mediated cytotoxicity (ADCC) (Parsons
et al., 2012). Evidence suggests that the synergistic impact of
these loci begins soon after infection, given that the strongest
effect was on CD4+ T cell decline. A link between innate immune
function and disease outcome is further supported by the recent
demonstration of viral evolution under NK-mediated immune
selection pressure, demonstrated indirectly by sequence evolu-
tion that maps to NK cell immune pressure (Alter et al., 2011).
These sequence polymorphisms in HIV have been shown to
enhance binding of inhibitory KIRs to ligands on infected CD4+
T cells, thus reducing the antiviral effect NK cells and further
suggesting the importance of the KIR-HLA interaction in modu-
lating of disease.
Another binding partner for HLA class I is a group of immuno-
modulatory molecules called leukocyte immunoglobulin-like
receptors (LILRs) expressed on dendritic cells (DCs), which
regulate the functional properties of DCs and thereby influence
overall immune activation (Lichterfeld and Yu, 2012). It has
been suggested that immune function may be influenced by
binding of certain HLA alleles to ILT4, one of the LILRs on
dendritic cells (Huang et al., 2010; Huang et al., 2009), but further
studies are needed to define the relative contribution of this inter-
action with HLA to HIV control.
Epitope-Dependent Mechanisms of MHC
Class I-Mediated Control of HIV
Recognition of infected cells depends on CD8+ T cell recognition
of a complex consisting of viral peptide andHLA class I; thus, the
HLA-peptide complex clearly plays a role, as outlined above.
However, additional variables, including the kinetics of HLA-
peptide expression and the impact of immune selection events
on viral evolution that occur through this process, suggest that
the actual epitopes presented by HLA class I alleles can be
expected to play a role as well.
HIV Epitope Targeting and Viral Load
The dominant epitopes restricted by the MHC class I that have
been linked with immune control of immunodeficiency virus
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typically adopted to evaluate the contribution of a particular
epitope to immune control has been to compare viral loads
in HLA-matched study subjects who do or do not make
particular CD8+ T cell responses (Kiepiela et al., 2004), although
this requires large populations in order to adequately correct
for multiple comparisons. The HLA-B*57 responses toward
the Gag epitopes TSTLQEQIAW (‘‘TW10,’’ Gag 240–249) and
KAFSPEVIPMF (‘‘KF11,’’ Gag 162–172) have been linked with
substantially lower viral loads in HLA-B*57-positive subjects
who show responses to these epitopes, whereas a response
to the B*57-restricted Vif epitope LGHGVSIEW is associated
with high viral loads (Kiepiela et al., 2007). Longitudinal studies
in HLA-B*57:01-positive subjects with variable rates of disease
progression, in this case defined by set point CD4 counts, also
show epitope-specific targeting is associated with outcome:
CD8+ T cell responses to TW10 and IW9 (ISPRTLNAW, Gag
147–155) are more polyfunctional and robust in those with
delayed progression (Norstro¨m et al., 2012). Similarly, the HLA-
B*27-restricted response toward the Gag epitope KRWIILGLNK
(‘‘KK10,’’ Gag 263–272) is linked with lower viral loads in HLA-
B*27-positive subjects (Ammaranond et al., 2011; Feeney
et al., 2004; Goulder et al., 1997). Although transmission studies
remain somewhat anecdotal, there is evidence that transmission
to HLA-B*57- or HLA-B*27-positive persons of viruses carrying
escapemutants in these particular epitopes results in more rapid
progression (Crawford et al., 2009; Goulder et al., 2001).
The Role of HIV-1 Gag
Numerous studies have linked viral load or disease outcome
to CD8+ T cell targeting of HIV-1 Gag (Dinges et al., 2010;
Edwards et al., 2002; Geldmacher et al., 2007; Kiepiela et al.,
2007; Klein et al., 1995; Masemola et al., 2004; Novitsky et al.,
2003; Ogg et al., 1998; Rivie`re et al., 1995; Streeck et al., 2007;
Zun˜iga et al., 2006). The mechanism of this effect may involve
at least two different aspects related to Gag specificity. The first
is that Gag is so highly abundant within the virus entering CD4+
T cell target cells that Gag epitopes can be processed, bind
with developing class I molecules, and be expressed on the
cell surface and recognized by Gag-specific CD8+ effector
T cells within a few hours of infection (Chen et al., 2012a; Payne
et al., 2010; Sacha et al., 2007a), comfortably prior to de novo
synthesis of viral proteins including Nef, whose effects include
downregulation of HLA class I that impairs CD8+ T cell recogni-
tion (Collins et al., 1998). This same property appears to also
apply to Pol, which is present on incoming virions, although in
smaller amounts (Chen et al., 2012a; Sacha et al., 2007b). The
second aspect of a Gag-specific response, particularly if one
considers the capsid protein p24 Gag, is that the amino acid
sequence is highly conserved, implying that a significant fitness
cost would probably result from any sequence changes (Marti-
nez-Picado et al., 2006; Miura et al., 2009a). Thus, although
escape mutations may be selected by the virus, enabling it to
evade potent CD8+ T cell responses, the consequence of these
mutations in p24 Gag may be a reduction in viral replicative
capacity (RC) and therefore an overall benefit to the host.
HLA-Associated Viral Mutations and Viral Fitness
In the case of the HLA-B*57 and HLA-B*27 p24 Gag epitopes
mentioned above, in each instance evaluated, the escape muta-
tions that are selected do indeed reduce viral RC (Crawford et al.,2009; Martinez-Picado et al., 2006; Miura et al., 2009b; Schnei-
dewind et al., 2008; Schneidewind et al., 2007). The most
commonly occurring escape mutations within the HLA-B*27
epitope KK10, involving the substitution at P2 of Arg by Lys,
causes such a reduction in RC that this escape mutation
evidently cannot be accommodated by the virus without a
compensatory mutation (S173A) arising simultaneously 91
amino acids upstream in a location closely adjacent in the 3D
structure of the capsid protein to the R264K escape mutation
(Schneidewind et al., 2007). This requirement for two mutations
simultaneously may in part explain the many years it typically
takes for someone who has HLA-B*27 to lose immune control
of HIV infection. In the case of the HLA-B*57 p24 Gag epitopes,
there are three of these, and accumulating mutations in these
epitopes each contributes to progressive loss of viral RC such
that, once all the mutations are in place, a substantially attenu-
ated virus remains (Crawford et al., 2009). Even in elite control-
lers there is evidence of escape from CD8+ T cell responses
(Bailey et al., 2009; Miura et al., 2009c), with some data indi-
cating that the rarely observed escape mutants, which inflict
greatest damage to viral RC, are those that tend accompany
maintained control of viraemia (Miura et al., 2009a; Miura et al.,
2009b). This may be related to an enhanced ability of the partic-
ular TCR to recognize the commonly arising variants that inflict
only modest degree of damage to viral RC (Chen et al., 2012b).
It is noteworthy that, with the exception of HLA-A*32, the
dominant response restricted by all the protective HLA alleles
is in p24 Gag (Table 2). In contrast, the dominant responses
restricted by the HLA alleles associated with rapid progression
are more often in Nef or Env (Kiepiela et al., 2007; Ngumbela
et al., 2008). Numerous studies have demonstrated that a Gag-
specific response, and especially the breadth of the Gag-
specific CD8+ T cell response, is inversely correlated with viral
load (Dinges et al., 2010; Edwards et al., 2002; Geldmacher
et al., 2007; Kiepiela et al., 2007; Masemola et al., 2004; Novitsky
et al., 2003; Ogg et al., 1998; Rivie`re et al., 1995; Streeck et al.,
2007; Zun˜iga et al., 2006), whereas the reverse is the case for
Nef- or Env-specific responses (Dinges et al., 2010; Kiepiela
et al., 2007; Masemola et al., 2004; Rivie`re et al., 1995). There
is also evidence that escape mutants in Env epitopes tend to
have little impact on viral RC, in comparison to those that arise
within Gag (Troyer et al., 2009), such that HLA alleles presenting
Env epitopes may have less antiviral efficacy.
Micropolymorphism studies, in which HLA class I molecules
are compared that differ by one, or a small number of, amino
acids, have been illuminating here. Two closely related HLA-B
alleles, HLA-B*42:01 and HLA-B*42:02, differ by a single amino
acid, with Tyr and His at HLA position 9, respectively, which
lies at the base of the peptide-binding groove (Marsh et al.,
2000). Both express the Bw6 motif and therefore do not act as
KIR ligands. Both are in LD with the same HLA-A and HLA-C
alleles (HLA-A*30:01 and HLA-C*17:01), and therefore the
impact via LD of other HLA alleles on the differential effects
observed for HLA-B*42:01 and HLA-B*42:02 is minimized.
Although the peptide-binding motif of these two molecules
appears indistinguishable, in practice the epitopes targeted by
individuals expressing HLA-B*42:01 and HLA-B*42:02 differ
dramatically. Most notably, HLA-B*42:01 presents multiple
Gag epitopes, including TPQDLNTML (‘‘TL9,’’ Gag 180–189),Immunity 37, September 21, 2012 ª2012 Elsevier Inc. 433
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ences are also associated with a 0.52 log10 lower viral load set
point in subjects with HLA-B*42:01, consistent with the notion
of Gag responses generally affording some protection against
disease progression (Kløverpris et al., 2012). For comparison,
the average reduction in viral set point resulting from expressing
of HLA-B*57:03 is 0.75 log10 (Carlson et al., 2012).
Monkey studies also support a role for Gag targeting in the
context ofMHC class I alleles and immune control. Burmese rhe-
sus macaque animals carrying the 90-120-Ia haplotype vacci-
nated with a DNA-prime, Gag-expressing Sendai virus vector
boost and then challenged with SIVmac239 were able to control
viraemia to undetectability, compared to controls whose viral set
points were in the 104–106 range (Matano et al., 2004). The
epitopes identified as responsible were IINEEAADWDL (‘‘IL11,’’
Gag 206–216) and SSVDEQIQW (‘‘SW9,’’ Gag 241–249). Escape
mutations arise early in the course of infection in IW11 (L216S)
and later in SW9 (D244E) that both reduce viral RC (Kawada
et al., 2007; Matano et al., 2004). Moreover, infection of vacci-
nated 90-120-Ia-positive macaques with a virus carrying these
mutants resulted in failure of these animals to control viraemia
(Kawada et al., 2008). Animals expressing the 90-120-Ia haplo-
type that were vaccinated with a construct expressing the
single epitope SW9 were able to control postchallenge viraemia
(Tsukamoto et al., 2009), as were animals vaccinated with a
construct expressing the single epitope IL11 (Ishii et al., 2012),
indicating that induction of a single epitope-specific response,
properly targeted in the correct MHC context, may be sufficient
for a vaccine to be effective. These experiments closely re-
semble what is observed in HLA-B*57-positive humans who
control HIV infection, in whom the dominant response in
acute infection is toward an epitope TSTLQEQIAW (‘‘TW10’’)
that is precisely homologous to the protective SIV epitope
SSVDEQIQW (‘‘SW9’’) (Table 2).
Data such as these suggest a role for protein specificity and
also for the particular epitope being targeted, independent of
the MHC effect. The epitopes identified as playing a part in
immune control of SIV infection and of HIV infection are, as
illustrated above, in many cases virtually identical, in spite of
the vast phylogenetic distance between the MHC class mole-
cules restricting them and the sizeable distance between HIV
and SIV. In addition to Mamu-A1*065:01-SW9 and HLA-B*57/
5801-TW10, these include Mamu-A1*043:01-IW11 and HLA-
A*25-EW10, Mane-A*10-KP9 and HLA-B*57-KF11, and Mamu-
A*01-CM9 and HLA-B*42/81-TL9 (Table 2). However, it should
be emphasized that, just as the expression of HLA-B*57 does
not necessarily translate into immune control of HIV infection,
the generation of Gag-specific responses also does not confer
universal protection against disease progression. Likewise,
targeting of an identical epitope in the context of different class
I alleles results can result in very different mutational escape,
which probably impacts T cell efficacy (Leslie et al., 2006).
However, the data presented above suggest that, like expres-
sion of HLA-B*57, a broad Gag-specific response in general is
a factor that is likely to contribute to improved control of HIV
infection.
Influence of Epitopes outside Gag
Studies in the macaque-SIV model have, on the whole, sup-
ported the role of Gag-specificity and the impact of escape434 Immunity 37, September 21, 2012 ª2012 Elsevier Inc.mutants on viral RC in CD8+ T cell-mediated immune control of
immunodeficiency virus infection. However, the work on Indian
rhesus elite controllers of SIV has also highlighted the fact that
effective CD8+ T cell responses can be found outside of Gag.
Among Mamu-B*08 and Mamu-B*17 elite controller macaques,
the epitopes mediating control are not in Gag, but in Nef or Vif
(Maness et al., 2008; Valentine et al., 2009). Mamu-B*08 animals
infected with SIVmac239 containing mutants in the key non-Gag
epitopes were unable to contain viraemia as successfully as
those infected with wild-type virus (Valentine and Watkins,
2008). Mamu-B*08 animals vaccinated with constructs express-
ing the three critical epitopes in Nef and Vif showed markedly
improved control of viraemia compared with unvaccinated
animals (Mudd et al., 2012). Moreover, the mechanism impli-
cated here does not appear to involve the cost to viral RC of
escape mutants. Likewise, in HIV infection there is evidence of
effective antiviral pressure, as measured by effective inhibition
of virus replication in vitro, directed against epitopes other than
Gag, including Env and Nef (Chen et al., 2012a; Chen et al.,
2011; Yang et al., 1997).
Thus, although the epitopes that form the dominant CD8+
T cell responses may play an important part in contributing to
immune control because of features relating to protein speci-
ficity, the MHC class I molecule itself evidently also performs a
critical role in establishing the effectiveness of particular CD8+
T cell responses. The absence to date of an identified HLA class
I molecule that protects against HIV disease progression and yet
does not have a dominant Gag-specific response continues to
obscure the precise role of epitope and HLA in immune control.
The Special Case of HLA-C
One aspect of HLA-mediated control of HIV that still remains
quite unclear is the role of HLA-C. Several GWAS in Caucasians
have shown that a SNP 35 kb upstream of the HLA-C locus is
strongly associated with viral set point (Fellay et al., 2009; Fellay
et al., 2007; Pereyra et al., 2010). The protective CC variant is
linked with high HLA-C expression (Thomas et al., 2009), and
variation at 35 marks a polymorphism within the 30 UTR of
HLA-C that regulates binding of a microRNA to its target site,
which has been shown to regulate HLA-C expression (Kulkarni
et al., 2011). Strong binding of this microRNA (hsa-miR-148)
results in relatively low expression of HLA-C, whereas alleles
that do not bind this microRNA have high HLA-C expression.
Of note, however, the 35 C variant is in strong LD with HLA-C
alleles that are themselves in strong LD with protective HLA-B
alleles in Caucasian cohorts (Corrah et al., 2011). Examples
here are HLA-C*02:02 and HLA-B*27:05, HLA-C*06:02 and
HLA-B*57:01, HLA-C*0801/02 and HLA-B*14, and HLA-
C*12:02 and HLA-B*52. The 35 T variant is in LD with HLA
alleles such as HLA-C*07:01, which is in tight LD with the risk
allele HLA-B*08:01. The fact that the 35 SNP is also present
in African American cohorts but does not correlate with viral
set point in those populations (McLaren et al., 2012; Pelak
et al., 2010; Shrestha et al., 2009) might relate to the different
patterns of LD between HLA-B and HLA-C alleles referred to
above. The protective HLA-B alleles in African cohorts include
HLA-B*57:03 and HLA-B*58:01, which are both in LD with
HLA-C*07:01, a low-expressing allele, and the principal risk
allele HLA-B*58:02, which is in strong LD with HLA-C*06:02,
Figure 2. Potential Mechanisms of HLA-
Associated Impact on Viral Control
The HLA class I molecule is a heterodimer con-
sisting of three alpha helices and b-2 micro-
globulin. The alpha 1 and alpha 2 domains
together form the peptide binding groove, which
presents viral peptides at the surface of an in-
fected cell, and this complex is in turn recognized
by the T cell receptor on CD8+ T cells, through
interactions with both the TCR and CD8 receptor
(shown). The HLA molecule or peptide-HLA
complex may also bind KIR and LILR (not shown).
The mechanisms by which HLA and its interac-
tions with CD8+ T cells, TCR, epitope, and infected
cells, as well as HLA-specific mechanisms, have
been shown to modulate the efficacy of HIV
control are listed.
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control of HIV is likely to be facilitated and clarified by further
studies including direct measurement of expression levels of
different HLA-C alleles and involving different study populations.
Concluding Remarks and Future Directions
The discovery more than 15 years ago that HLA-B*57 and HLA-
B*27 are associated with improved HIV control (Kaslow et al.,
1996), followed by the association of HLA-B*35 with lack of
control (Carrington et al., 1999), has been consistently validated,
and the major impact of these and other HLA class I alleles on
disease progression has been further revealed as HLA typing
methods have improved and cohort sizes have expanded.
Initially, the evidence appeared to suggest that the epitope
presented by such HLA class I molecules was key to immuneImmunity 37, Secontrol. Loss of the critical epitope meant
loss of the protective effect associated
with the HLA allele, and there is strong
support for this for multiple but by no
means all epitopes, particularly those in
Gag. More recent data from studies in
humans and in the SIV-macaque model,
however, also indicate an important com-
ponent of HLA-associated immune con-
trol of HIV infection is related to the HLA
molecule itself, either through specific
characteristics of peptide binding or
through allele-specific interactions with
HLA ligands including TCRs on CD8
T cells, KIRs on NK cells, or LILRs on
dendritic cells.
It is likely, also, that the precise mecha-
nism underlying the protective effects of
MHC class I molecules may vary from
one to another. For example, there is
evidence that the beneficial effects of
HLA-B*57 and HLA-B*27 appear to differ
in their timing during the course of
HIV infection (Gao et al., 2005). Resolu-
tion of the relative contributions of these
different effects, and identification of the
precise mechanisms governing them,will require large population-based studies, ideally longitudinal
studies from the time of acute infection, and will probably reveal
multifactorial impacts on viral control.
The concepts of HLA molecules driving the evolution of HIV,
together with differential impacts of HLA alleles on disease
outcome, raise important questions as the quest for an HIV
vaccine continues. Despite HLA-specific associations with
disease outcome, it is important to note that even among
persons with protective alleles such as B*27 and B*57, the
majority of persons with these alleles progress, whereas some
persons with no protective alleles remain asymptomatic, sug-
gesting that host genetics are not an absolute constraint and
that HLA alone is poorly predictive of outcome. This raises the
question as to what other factors modulate the HLA effect
(Figure 2). Indeed, it is estimated that less than 20% of viralptember 21, 2012 ª2012 Elsevier Inc. 435
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polymorphisms (Carrington and Walker, 2012).
Basic concepts outlined in this review provide multiple poten-
tial paths toward better defining those components required for
effective durable control of HIV. The fitness landscape of HIV
needs to be defined, as efforts to harness immune responses
to impair viral replication capacity offer hope for enhanced con-
trol. The importance of Gag targeting is clear, but definition of
other non-Gag epitopes that can be beneficially targeted, partic-
ularly those that are associated with a fitness cost, need to be
a priority. The specific properties of HLA ligands in enhancing
immune control need to be better defined, and offer opportuni-
ties to improve immune control through TCR, KIR, and LILR
interactions. A better definition of the properties of the CD8
T cells that mediate infected cell killing, and how to enhance
this function, remains a priority. The path toward an HIV vaccine
has not been easy, and the ongoing evolution of HIV under HLA-
associated immune selection pressure is a significant challenge.
However, the prevalence and extent of HIV infection, together
with readily measureable clinical parameters of disease severity,
offer an unprecedented opportunity to dissect the multiple
parameters that contribute to immune control, which will have
benefit to harnessing the immune system well beyond HIV.
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